EP Patent

EP4225305A1 — Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Assigned to Bioxcel Therapeutics Inc · Expires 2023-08-16 · 3y expired

What this patent protects

Disclosed herein are methods and composition for treating bipolar disorders and psychosis by administering dexmedetomidine. The methods and composition alleviate mania, hypomania, psychosis, and depression in the subjects, providing improved therapeutic outcomes.

USPTO Abstract

Disclosed herein are methods and composition for treating bipolar disorders and psychosis by administering dexmedetomidine. The methods and composition alleviate mania, hypomania, psychosis, and depression in the subjects, providing improved therapeutic outcomes.

Drugs covered by this patent

Patent Metadata

Patent number
EP4225305A1
Jurisdiction
EP
Classification
—
Expires
2023-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Bioxcel Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.